SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
BMY Analysis & Videos »
BMY: Bull or Bear?
FDA Calendar Updates at BioMedReports.com
BMY
|
|
|
-5.36%
in
9 days
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st...
|
FDA Calendar Updates – Diabetes: AZN, BMY, NVO, Takeda
BMY
|
|
|
+5.13%
in
63 days
(closed on 06/25/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA ...
|
FDA, Clinical Trial Calendar Updates: Weight Loss, Diabetes, and More
BMY
|
|
|
-9.68%
in
22 days
(closed on 04/23/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 110 entries through 4/1/09. The FDA Calendar includes the following information: company name, ticker, decision d...
|
Upcoming FDA Advisory Panel Meetings
BMY
|
|
|
+16.34%
in
23 days
(closed on 04/01/09)
A trio of diabetes drug candidates are affected by a tougher stance at the FDA for this class of drugs, which is focused on cardiovascular risks such as heart attack and stroke. Two of the drugs will be reviewed at early April FDA advisory panel meeting while a third will likely require additional clinical trials. http://www.biomedreports.com/fda-calendar.html <> In December the FDA issued a new guidance document that recommended more stringent clinical trials for diabetes drugs to better assess heart attack and stroke risks. In a change that was effective immediately,...
|
Updated Clinical Trial and FDA Decision Calendars
BMY
|
|
|
+5.82%
in
5 days
(closed on 03/09/09)
Posted by: Mike Havrilla in Untagged on Mar 04, 2009 <!-- Post Teaser Text --> <> Below are some recent updates to the BioMedReports.com -- FDA and Clinical Trial Calendars : <> 1.) Auxilium Pharma (AUXL): 3/2/09 BLA submission with priority review request for XIAFLEX (clostridial collagenase for injection), a novel, first-in-class, orphan-designated biologic for the treatment of Dupuytren's contracture. 5/2/09 is the date for FDA to accept the filing for review and decide on prior...
|
Top Stock Picks '09: Bristol-Myers (BMY)
BMY
-9.58%
in
71 days
(closed on 03/17/09)
Filed under: Newsletters, Bristol-Myers Squibb (BMY), Stocks to Buy, Best Stocks for 2009 This post is part of a special annual report -- Top Stock Picks '09 -- in which TheStockAdvisors.com asked 75 leading newsletter advisors to select their favorite investment for the new year.  "My selection for 2009 is Bristol-Myers Squibb (NYSE: BMY)," says Chuck Carlson, the leading advisor in the area of dividend reinvestment plans.
<>In his The DRIP Investor, he explains, "This pharmaceutical company has a lot to offer investors, including a high yield, a rising profit stream, and a speculative kicker in...
|
Drug and health care stocks: The right prescription for 2009
BMY
+0.60%
in
2 hours
(closed on 01/05/09)
Filed under: Pfizer (PFE), Newsletters, Johnson and Johnson (JNJ), Bristol-Myers Squibb (BMY), Stocks to Buy, Best Stocks for 2009  Health care has long been considered a recession-resistant business. Given the current economic challenges, it's little surprise that in our survey of favorite stocks for the coming year, a number of leading advisors turned to this classic defensive sector.
<>In this year's Top Stock Picks from 75 advisors report, we found an intriguing group of medical-related stocks, from speculation in emerging biotech to well-established pharmaceutical firms, and from medical pr...
|
Stock Picks for Healthy Returns
BMY
|
|
|
-12.53%
in
98 days
(closed on 03/04/09)
<> Abbott Labs (ABT) is a consistent performer with diversified healthcare operations, including pharmaceuticals, diagnostics, medical nutrition products, and medical devices/stents. ABT is back to the lower end of its trading range near 50 bucks, presenting an excellent entry point with a 2.8% dividend yield and forward PE of about 14X.
Celgene (CELG) is also trading at the low end of its trading range around 50 bucks as a large-cap growth stock focused on cancer biotech products and research with an estimated PEG ratio below one.
...
|
Dissecting Defensive Dividend Stocks & ETFs
BMY
|
|
|
+0.20%
in
6 days
(closed on 11/25/08)
<> 
The accompanying table includes 47 U.S.-listed companies with market caps over $10B and dividend yields over 5%, excluding all companies from the following sectors or industry groups: finance, insurance, consumer cyclical products, retailers, and basic materials in favor of healthcare, consumer staples such as tobacco, telecom services, energy, and utilities. Also, the following dividend ETFs are included in the table as a comparison:
1.) iShares Dow Jones Select Dividend (DVY)
2.) WisdomTree Dividend Top 1...
|
ImClone Set to Sell at a Premium to Mystery Bidder
BMY
|
|
|
-11.29%
in
12 days
(closed on 10/11/08)
ImClone Systems (IMCL) is set to sell itself for $6.1B or about $70 per share to the mystery big pharma bidder that Chairman Carl Icahn introduced as a defense against Bristol-Myers (BMY) original offer of $60, which was recently upped to $62 per share for the remaining 83% stake it does not already own. I have written about the saga on my blog since the end of July when Bristol-Myers made the original offer, but the Wall Street Journal s reporting the most likely bidders are Pfizer (PFE) or Eli Lilly (LLY).
Both of these big pharmas are in need of a pipeline and have the cash to...
|
Eli Lilly Sinks After Hours on Effient Delay
BMY
|
|
|
+0.00%
in
1 day
(closed on 09/29/08)
<> 
Eli Lilly (LLY) and Daiichi Sankyo (Tokyo: 4568) announced on Friday evening that the FDA had not completed its regulatory review for its blood thinner drug, which would go by the brand name of Effient (prasugrel). The FDA previously delayed its decision by three months earlier this summer, but in this case no new deadline was set by the agency. Shares of Eli Lilly slid by about 4% after hours on less than 100,000 shares traded, closing near its 52-week low at $45.01 per share on Friday evening. However, the current sli...
|
FDA Decision Date Calendar for 2009
BMY
|
|
|
+1.68%
in
4 days
(closed on 09/28/08)
<> 
<> <> <> The accompanying table presents a calendar of expected FDA regulatory approval decisions for 2009, including a March 1st deadline to expand the label of cancer drug Erbitux in what has now become a hostile takeover attempt by Bristol-Myers (BMY) for the remaining 83% stake in ImClone Systems (IMCL) it does not already own. Two other companies which are highly leveraged to their upcoming FDA decision include Pain Therapeutics (PTIE) and King Pharma (KG) for Remoxy, which are due to hear back from the agency this yea...
|
Bristol-Myers Ups Bid to $62 for ImClone
BMY
|
|
|
-2.04%
in
1 day
(closed on 09/24/08)
<> 
Last night, Bristol-Myers (BMY) announced plans to increase its bid for the remaining 83% of ImClone Systems (IMCL) it does not already own to $62 per share and plans to take the offer directly to shareholders in the form of a tender offer. ImClone and Chairman Carl Icahn rejected a $60 per share cash bid from Bristol-Myers at the end of July and stated that a mystery big pharma bidder had emerged at $70 per share, as I last wrote about here . Besides Bristol-Myers 17% stake in ImClone, the two companies are marketing pa...
|
People Bullish on BMY
People Bearish on BMY
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Be the first to start a discussion and earn 2 points.
More Resources
|
"Wall Street has been nonplussed about results from 
About BristolMyers Squibb Company
- Answers.com
